TLSI
TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc. (TLSI) has 16 SEC Form 4 filings (22 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Jul 6, 2026.
Insiders have net bought $1.8M over the trailing 6 months. The largest single insider purchase in this window was $1.5M by Director Stansky Michael P on May 15, 2026.
Insider Buying
$1.8M
reported purchases (SEC code P)
Insider Selling
$1K
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Market Cap
$260.4M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Marshak RichardFirst filing | Chief Commercial Officer | Sale | 543 | $1K | May 19 | SEC ↗ |
Stansky Michael PFirst filing | Director | Purchase | 610,000 | $1.5M | May 18 | SEC ↗ |
Szela Mary TFirst filing | CEO and President | Purchase | 39,682 | $103K | May 18 | SEC ↗ |
Wahlstrom MatsFirst filing | Director | Purchase | 60,000 | $152K | May 18 | SEC ↗ |
Patience DavidFirst filing | Chief Financial Officer | Purchase | 7,100 | $17K | May 18 | SEC ↗ |
Gordon Gary B.First filing | Director | Purchase | 10,000 | $25K | May 18 | SEC ↗ |
Related companies
TriSalus Life Sciences, Inc. is in the Healthcare sector.